<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04950803</url>
  </required_header>
  <id_info>
    <org_study_id>RECOVERY</org_study_id>
    <nct_id>NCT04950803</nct_id>
  </id_info>
  <brief_title>A Randomised-controlled Trial of an Oral Microbiome Immunity Formula in Recovered COVID-19 Patients</brief_title>
  <official_title>A Randomised-controlled Trial of an Oral Microbiome Immunity Formula in Reducing Development of Long-term Co-morbidities in Recovered COVID-19 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the effectiveness of an oral microbiome immunity formula in&#xD;
      modulating gut microbiota, enhancing immunity and reducing long-term complications and&#xD;
      co-morbidities in patients who have recovered from COVID-19.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SARS-CoV-2, the cause of COVID-19, emerged as a new zoonotic pathogen of humans at the end of&#xD;
      2019 and rapidly developed into a global pandemic. It may develop severe or critical disease&#xD;
      with respiratory failure requiring oxygen support and intensive care.&#xD;
&#xD;
      Natural infection by virus triggers an effective system immunity so that the host can resist&#xD;
      or highly reduce the chance of re-infection.&#xD;
&#xD;
      In many cases, this protection can maintain a long period of time. However, the long-term&#xD;
      immunities (over a year) and complications from the patients are not yet very clear. We found&#xD;
      that COVID-19 survivors who have cleared the virus continued to have persistent altered gut&#xD;
      microbiota and up to 80 percent had residue COVID-19 related symptoms including fatigue,&#xD;
      difficulty in breathing, impaired memory and hair loss up to 6 months after discharge (LONG&#xD;
      COVID-19).&#xD;
&#xD;
      Earlier studies from our CU Medicine have shown a link between altered gut microbiome and&#xD;
      COVID-19 severity, and more patients who received a novel microbiome immunity formula (SIM01)&#xD;
      achieved complete symptom resolution and developed neutralising antibody than those who did&#xD;
      not (unpublished data). Research from the Faculty also reported that almost 40% of people in&#xD;
      Hong Kong had significant gut dysbiosis especially in elderly and patients with diabetes,&#xD;
      obesity or chronic diseases.&#xD;
&#xD;
      This study is a multi-centre, triple-blind, randomized, placebo-controlled clinical trial&#xD;
      that aims to evaluate the effectiveness of an oral microbiome immunity formula (SIM01)&#xD;
      invented by the Chinese University of Hong Kong (CUHK) in modulating gut microbiota,&#xD;
      enhancing immunity and reducing long-term complications and co-morbidities (e.g. sepsis,&#xD;
      cardiopulmonary complications, metabolic syndrome, neuropsychiatric disorders) in patients&#xD;
      who have recovered from COVID-19.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 25, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Any comorbidities</measure>
    <time_frame>6 months</time_frame>
    <description>A composite outcome of any comorbidities, including clinical manifestations of long-COVID, hospitalizations due to sepsis, cardiopulmonary complications, metabolic syndrome and neuropsychiatric disorders</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Any comorbidities</measure>
    <time_frame>24 months</time_frame>
    <description>A composite outcome of any comorbidities, including clinical manifestations of long-COVID, hospitalizations due to sepsis, cardiopulmonary complications, metabolic syndrome and neuropsychiatric disorders</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increase in metabolic syndrome (MetS) score</measure>
    <time_frame>24 months</time_frame>
    <description>a validated index computed from an analysis based on waist circumference, fasting triglycerides, fasting glucose, and systolic blood pressure, calculated in score (1-5), higher levels indicated higher probability of presence of metabolic syndrome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increase in other system-specific comorbidities</measure>
    <time_frame>24 months</time_frame>
    <description>Increase in other system-specific comorbidities involving cardiovascular, gastrointestinal, liver, renal, genitourinary, haematological, and neurological systems</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healthcare service utilization</measure>
    <time_frame>24 months</time_frame>
    <description>The frequency of healthcare service (including clinics and Accident and Emergency) that the subject has attended</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-reported long-COVID-19 symptoms</measure>
    <time_frame>24 months</time_frame>
    <description>Subjects will fill in a survey whether they have long-COVID-19 symptoms (e.g. cough, fatigue, etc) and grade the symptoms. The higher the score, the worse the outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Quality of life</measure>
    <time_frame>48 months</time_frame>
    <description>Changes in Quality of life using visual analogue scale, score ranging 0-100. The higher the score, the better the outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in faecal microbial and bacterial metabolites</measure>
    <time_frame>48 months</time_frame>
    <description>Shotgun metagenomics and metabolomics sequencing of faecal samples at baseline and each visit will be used to generate serial gut microbial taxonomic and bacterial functional profiles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood immunity profiles</measure>
    <time_frame>24 months</time_frame>
    <description>To characterize immune cell phenotypes in peripheral blood mononuclear cells (PBMCs), we will evaluate multiple cytokines and chemokines in plasma samples using MILLIPLEX MAP Human Cytokine/ Chemokine Magnetic Bead Panel.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>COVID-19</condition>
  <condition>Probiotic</condition>
  <arm_group>
    <arm_group_label>Active arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will take microbiome immunity formula (SIM01) daily for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will take active vitamin daily for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Microbiome immunity formula</intervention_name>
    <description>Microbiome immunity formula contains probiotics blend (3Bifidobacteria, 10 billion CFU per sachet)</description>
    <arm_group_label>Active arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Active placebo</intervention_name>
    <description>Active placebo contains active vitamin</description>
    <arm_group_label>Placebo arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Individuals aged 18 and above;&#xD;
&#xD;
          2. Subjects who are mentally capable to participate in the study and provide informed&#xD;
             consent;&#xD;
&#xD;
          3. Subjects who can communicate in Chinese or English;&#xD;
&#xD;
          4. Subjects who are ambulatory and do not have difficulties travelling to the clinics for&#xD;
             follow-up;&#xD;
&#xD;
          5. Subjects who do not have plans to leave Hong Kong in the subsequent two years after&#xD;
             recruitment; and&#xD;
&#xD;
          6. Subjects who agree to give informed consent voluntarily.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who are unable to receive oral fluids;&#xD;
&#xD;
          2. Subjects who have received surgery involving the intestine within past 30 days;&#xD;
&#xD;
          3. Subjects who are pregnant or breastfeeding; and&#xD;
&#xD;
          4. Subjects who are immunocompromised, e.g. on cancer treatment, bone marrow/organ&#xD;
             transplant, immune deficiency, poorly controlled HIV/AIDS.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Siew Ng</last_name>
    <role>Principal Investigator</role>
    <affiliation>CUHK-M&amp;T</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kristy Ho</last_name>
    <phone>35053855</phone>
    <email>hiutungho@cuhk.edu.hk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amy Li</last_name>
    <phone>26373225</phone>
    <email>amyli@cuhk.edu.hk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Siew Chien Ng, PhD</last_name>
      <phone>35053996</phone>
      <email>siewchienng@cuhk.edu.hk</email>
    </contact>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <link>
    <url>https://www.who.int/emergencies/diseases/novel-coronavirus-2019</url>
    <description>WHO website</description>
  </link>
  <link>
    <url>https://www.coronavirus.gov.hk/eng/index.html</url>
    <description>Hong Kong Government website</description>
  </link>
  <link>
    <url>https://clinicaltrials.gov/ct2/show/NCT04376658?cond=long+covid+outcome&amp;draw=2&amp;rank=2</url>
    <description>Quality of Life and Long-term Outcomes After Hospitalization for COVID-19.</description>
  </link>
  <reference>
    <citation>Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24. Erratum in: Lancet. 2020 Jan 30;:.</citation>
    <PMID>31986264</PMID>
  </reference>
  <reference>
    <citation>Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.</citation>
    <PMID>32109013</PMID>
  </reference>
  <reference>
    <citation>Ngai JC, Ko FW, Ng SS, To KW, Tong M, Hui DS. The long-term impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and health status. Respirology. 2010 Apr;15(3):543-50. doi: 10.1111/j.1440-1843.2010.01720.x. Epub 2010 Mar 19.</citation>
    <PMID>20337995</PMID>
  </reference>
  <reference>
    <citation>Li TS, Gomersall CD, Joynt GM, Chan DP, Leung P, Hui DS. Long-term outcome of acute respiratory distress syndrome caused by severe acute respiratory syndrome (SARS): an observational study. Crit Care Resusc. 2006 Dec;8(4):302-8.</citation>
    <PMID>17227266</PMID>
  </reference>
  <reference>
    <citation>Martin JE, Louder MK, Holman LA, Gordon IJ, Enama ME, Larkin BD, Andrews CA, Vogel L, Koup RA, Roederer M, Bailer RT, Gomez PL, Nason M, Mascola JR, Nabel GJ, Graham BS; VRC 301 Study Team. A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. Vaccine. 2008 Nov 25;26(50):6338-43. doi: 10.1016/j.vaccine.2008.09.026. Epub 2008 Sep 26.</citation>
    <PMID>18824060</PMID>
  </reference>
  <reference>
    <citation>Modjarrad K, Roberts CC, Mills KT, Castellano AR, Paolino K, Muthumani K, Reuschel EL, Robb ML, Racine T, Oh MD, Lamarre C, Zaidi FI, Boyer J, Kudchodkar SB, Jeong M, Darden JM, Park YK, Scott PT, Remigio C, Parikh AP, Wise MC, Patel A, Duperret EK, Kim KY, Choi H, White S, Bagarazzi M, May JM, Kane D, Lee H, Kobinger G, Michael NL, Weiner DB, Thomas SJ, Maslow JN. Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial. Lancet Infect Dis. 2019 Sep;19(9):1013-1022. doi: 10.1016/S1473-3099(19)30266-X. Epub 2019 Jul 24.</citation>
    <PMID>31351922</PMID>
  </reference>
  <reference>
    <citation>Perera RA, Mok CK, Tsang OT, Lv H, Ko RL, Wu NC, Yuan M, Leung WS, Chan JM, Chik TS, Choi CY, Leung K, Chan KH, Chan KC, Li KC, Wu JT, Wilson IA, Monto AS, Poon LL, Peiris M. Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020. Euro Surveill. 2020 Apr;25(16). doi: 10.2807/1560-7917.ES.2020.25.16.2000421.</citation>
    <PMID>32347204</PMID>
  </reference>
  <reference>
    <citation>Bonifacius A, Tischer-Zimmermann S, Dragon AC, Gussarow D, Vogel A, Krettek U, Gödecke N, Yilmaz M, Kraft ARM, Hoeper MM, Pink I, Schmidt JJ, Li Y, Welte T, Maecker-Kolhoff B, Martens J, Berger MM, Lobenwein C, Stankov MV, Cornberg M, David S, Behrens GMN, Witzke O, Blasczyk R, Eiz-Vesper B. COVID-19 immune signatures reveal stable antiviral T cell function despite declining humoral responses. Immunity. 2021 Feb 9;54(2):340-354.e6. doi: 10.1016/j.immuni.2021.01.008.</citation>
    <PMID>33567252</PMID>
  </reference>
  <reference>
    <citation>Rupp J, Dreo B, Gütl K, Fessler J, Moser A, Haditsch B, Schilcher G, Matzkies LM, Steinmetz I, Greinix H, Stradner MH. T Cell Phenotyping in Individuals Hospitalized with COVID-19. J Immunol. 2021 Apr 1;206(7):1478-1482. doi: 10.4049/jimmunol.2001034. Epub 2021 Feb 8.</citation>
    <PMID>33558375</PMID>
  </reference>
  <reference>
    <citation>Legros V, Denolly S, Vogrig M, Boson B, Siret E, Rigaill J, Pillet S, Grattard F, Gonzalo S, Verhoeven P, Allatif O, Berthelot P, Pélissier C, Thiery G, Botelho-Nevers E, Millet G, Morel J, Paul S, Walzer T, Cosset FL, Bourlet T, Pozzetto B. A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity. Cell Mol Immunol. 2021 Feb;18(2):318-327. doi: 10.1038/s41423-020-00588-2. Epub 2021 Jan 6.</citation>
    <PMID>33408342</PMID>
  </reference>
  <reference>
    <citation>Hillier TA, Rousseau A, Lange C, Lépinay P, Cailleau M, Novak M, Calliez E, Ducimetière P, Balkau B; D.E.S.I.R. Cohort. Practical way to assess metabolic syndrome using a continuous score obtained from principal components analysis. Diabetologia. 2006 Jul;49(7):1528-35. Epub 2006 May 16.</citation>
    <PMID>16752171</PMID>
  </reference>
  <reference>
    <citation>DeMets DL, Lan KK. Interim analysis: the alpha spending function approach. Stat Med. 1994 Jul 15-30;13(13-14):1341-52; discussion 1353-6.</citation>
    <PMID>7973215</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 21, 2021</study_first_submitted>
  <study_first_submitted_qc>July 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 6, 2021</study_first_posted>
  <last_update_submitted>July 2, 2021</last_update_submitted>
  <last_update_submitted_qc>July 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Siew Chien NG</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

